Thank you.
I'll maybe begin with Mr. Mizzen.
You spoke of the PMPRB. I'm not fluent with all of these acronyms that we use. I'm learning about the issues behind this. We heard testimony from Merck—I believe, yesterday—in Quebec City. They warned of catastrophic consequences for investment in pharmaceutical research as a potential consequence of these proposals, if I understood them correctly.
Can you comment on that? You're supporting this. Do you disagree, perhaps, with other critics, or are these different problems that are perhaps not your problems? Tell me what the arguments are for and against these changes.